COX-2 expression in adenoma: An imperfect marker for chemoprevention

Gut

Volumn 59, Issue 5, 2010, Pages 568-569

  Chan, Andrew T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; BIOLOGICAL MARKER; CYCLOOXYGENASE 2; ICOSANOID; LYSINE ACETYLSALICYLATE; PLACEBO; PROSTAGLANDIN;

CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; DISEASE MARKER; ENZYME INHIBITION; HUMAN; IMMUNOHISTOCHEMISTRY; NOTE; POLYPECTOMY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOMA; ANTICARCINOGENIC AGENTS; ASPIRIN; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; HUMANS; LYSINE; NEOPLASM RECURRENCE, LOCAL; TUMOR MARKERS, BIOLOGICAL;

EID: 77951738836     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.200014     Document Type: Note

References (13)

1. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-899 (Pubitemid 36297997)
2. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-890 (Pubitemid 36297996)
3. Benamouzig R, Deyra J, Martin A, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003;125: 328-336 (Pubitemid 36929412)
4. Logan RF, Grainge MJ, Shepherd VC, et al. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 2008;134:29-38. (Pubitemid 350309319)
5. Benamouzig R, Uzzan B, Martin A, et al. Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention. Gut 2010;59:622-629.
6. Markowitz SD. Aspirin and colon cancere - targeting prevention? N Engl J Med 2007;356: 2195-2198.
7. Cole BF, Logan RF, Halabi S, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 2009;101:256-266.
8. Eberhart CE, Coffey RJ, Radhika A, et al. Upregulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-1188 (Pubitemid 24294584)
9. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007;356:2131-2142 (Pubitemid 47010839)
10. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009;302:649-658.
11. Shen L, Kondo Y, Rosner GL, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005;97:1330-1338 (Pubitemid 41487800)
12. Delage B, Rullier A, Capdepont M, et al. The effect of body weight on altered expression of nuclear receptors and cyclooxygenase-2 in human colorectal cancers. Nutr J 2007;6:20. (Pubitemid 47583473)
13. Yan M, Myung SJ, Fink SP, et al. 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci U S A 2009;106:9409-9413.